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Abstract 
Throughout history, Mycobacterium tuberculosis (MTB) has killed more people than any 
other infectious agent, while Mycobacterium leprae is an ancient human pathogen that 
still causes disease today. Each has developed drug resistance, thus the discovery of 
potential novel antibiotic targets is essential. The diadenosine polyphosphatases 
(ApnAases) / mRNA decapping enzymes of the Nudix hydrolase superfamily have been 
found to be essential for a number of pathogens (Bartonella bacilliformis, Legionella 
pneumophila) to invade human host cells, a process often essential for pathogenesis, and 
thus potential novel drug targets. There are two ApnAases in MTB: Rv2985 and Rv3908 
and two corresponding orthologs in M. leprae: Ml1682 and Ml2698. Our laboratory has 
cloned, expressed, purified, and characterized Rv2985. Here, I describe the subcloning, 
expression, and partial purification of Rv3908, Ml1682, and Ml2698. The three genes 
were each subcloned to incorporate a His•Tag onto the N-terminus of each protein. Each 
His•Tagged protein was expressed and purified via Ni2+ affinity chromatography. The 
two ApnAases from M. leprae are fairly insoluble and thus a number of experiments were 
carried out aimed at increasing Ml1682’s solubility: varying expression temperature, 
Isopropyl-β-D-thiogalactopyranoside (IPTG) concentration, or time of expression after 
induction; the use of the chaperone GroESL, codon+ E. coli strain Rosetta(DE3), 
minimal media; or inclusion of glycylglycine. These standard methods of solubilization 
did not improve the solubility of this ApnAase from M. leprae, and thus other methods to 
improve solubility will need to be determined before we purify and characterize these 
enzymes.  Rv3908 is more soluble, and is ready to purify and characterize. 
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Abbreviations 
 
A.D. Anno Domini 
AIDS Acquired Immune Deficiency Syndrome 
ApnA Diadenosine polyphosphates 
B.C. Before Christ 
BB Borderline-Borderline 
BCG Bacillus Calmette-Guerin 
BL Borderline Lepromatous 
BT Borderline Tuberculoid 
CIAP Calf Intestinal Alkaline Phosphatase  
DLL Diffused Lepromatous Leprosy 
DOTS Directly Observed Therapy Short-course 
DTT Dithiothreitol 
E. coli Escherichia coli 
EDTA Ethylenediaminetetraacetic acid 
HIV Human Immunodeficiency Virus  
HT His•Tag 
IPTG Isopropyl-β-D-thiogalactopyranoside 
kbp Kilobasepairs 
KCl Potassium Chloride 
kDa Kilodalton 
kDMWCO Kilodalton Molecular Weight Cutoff 
LB Luria-Bertani 
LL Lepromatous Leprosy 
M. leprae Mycobacterium leprae 
M. lepromatosis Mycobacterium lepromatosis 
MDR-TB Multidrug Resistant TB 
Me7Gp3 5' 7-methyl guanosine cap 
mRNA messenger RNA 
MTB Mycobacterium tuberculosis 
MW Molecular Weight 
MWM Molecular Weight Marker 
MWMs Molecular Weight Markers 
NaCl Sodium Chloride 
Nudix Nucleoside diphosphate linked to some moiety “X” 
OD Optical Density 
PAGE Polyacrylamide Gel Electrophoresis 
PCR Polymerase Chain Reaction 
PEG Polyethylene Glycol 
RCF Relative Centrifugal Force 
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SDS Sodium Dodecyl Sulfate 
TB Tuberculosis 
TDR-TB Totally Drug Resistant TB 
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1. Introduction 
1.1 Leprosy 
1.1.1 Definition of Leprosy 
Leprosy is a rare but painful chronic infectious disease caused by Mycobacterium 
leprae and Mycobacterium lepromatosis. Though leprosy is not highly contagious, it does 
cause serious health issues for those who are infected. The bacteria seek out the coldest 
place they can find in the human body such as eyes, face, hands, and feet, affecting the 
eyes, nasal mucosa, skin, and peripheral nervous system,1,2 thus leading to vision 
problems, skin lesions, and the loss of extremities. Leprosy is characterized by the 
formation of nodules, ulceration, and the loss of sensation that leads to deformities, 
wasting of muscle, and paralysis.3 The exact routes of transmission are unknown, 
however it is believed that leprosy is mainly spread by nasal droplets or secretions from 
infected person to healthy person4 or from infected armadillo to healthy person.5 
 
1.1.2 Leprosy History  
Leprosy has existed since ancient times; it has been well documented by the oldest 
civilizations of Egypt, India, and China. It was first described in Egyptian papyrus around 
1550 B.C. and in Indian writings around 600 B.C.6 Greek records indicated that leprosy 
appeared in Greece in 62 B.C. after the army of Alexander the Great came back from 
India. At the same time in Rome, leprosy appeared after the return of Pompeii’s troops 
from Asia Minor.6  
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Throughout history, leprosy has been negatively judged and misunderstood. For a 
long time leprosy was thought to be a hereditary disease. Daniel Cornelius Danielssen 
(1815-1894), a Norwegian apothecary who studied leprosy and the skin doctor Carl 
Wilhelm Boeck published a book that depicted the difference between leprosy and other 
skin diseases with careful illustration and explanation.7 In their book, they described how 
leprosy developed only in people whose immune systems were compromised, and it 
seemed that the ability to resist the disease was genetically inherited. Since leprosy 
showed up in those with a family history of leprosy, they thought leprosy was an 
inherited disease. However, Danielssen’s protégé, Gerhard Henrik Armauer Hansen, did 
not agree that leprosy was an inherited disease. To prove his hypothesis, Hansen obtained 
a sample of tissue from a leprosy patient and examined it under the microscope, day after 
day for more than one year until he saw a group of little sticklike things growing on one 
of the sample plates. To prove that this tiny creature caused leprosy, he injected it into 
rabbits, but the rabbits remained healthy. Then, he injected the microorganism into a 
patient without her consent. The patient developed leprosy and thus sued Hansen. The 
court removed Hansen from his post at the hospital. Nonetheless, Hansen continued his 
work independently and eventually convinced the world that he found the causative agent 
of leprosy and named leprosy Hansen’s disease. 7 
Not only was leprosy mistakenly considered a hereditary disease prior to Hansen’s 
work, but also a curse of sinners, a punishment from God. This was because the disease 
could disfigure the hands and face, leaving a permanent mark, which many people 
thought was a sign of sin. In Europe, from the time of the Crusaders (AD 1095-1272) 
until the great plague epidemic of the fourteenth century, leprosy was widespread.7 
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During that time, if someone had leprosy, they were taken to the church, forced to wear 
special clothes or badges to distinguish them as unclean, and priests would stone them 
and curse them to death.7 Leprosy patients had to carry a bell or strike sticks together to 
warn others of their approach; they could not walk on narrow paths, could not speak 
above a whisper, and could not bathe in the village stream. In some places, they were not 
allowed in the markets or even in the town. In other regions, they were burned at the 
stake or buried alive.7  
Even after Hansen’s discovery that leprosy is a transmissible infectious disease, 
leprosy patients were stigmatized. In the late nineteenth century, the Louisiana Leper 
Home was established in Carville, Louisiana as the first leprosarium and refuge for 
leprosy patients. Patients were isolated from the rest of the world, needed permission to 
leave the leprosarium, and would be disgraced if they appeared in public.  
Treatment for leprosy was limited. In the early twentieth century, leprosy patients 
were treated with chaulmoogra nut oil, but this did not work for most patients. After the 
discovery of antibiotics, the antibiotic dapsone was discovered and became an effective 
drug treatment for leprosy starting in the 1950s. It worked wonderfully at first, until 
antibiotic resistance developed to dapsone. In 1981, the World Health Organization 
began recommending multi-drug therapy that finally made leprosy curable. Today, 
although leprosy is curable, every two minutes someone around the world is diagnosed 
with leprosy.8 The long fight is not over yet, and a leprosy vaccine is in the works. 
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1.1.3 Leprosy: Types and Transmission 
Prior to 2008, only one species of bacteria, Mycobacterium leprae, was known to 
cause leprosy. In 2008, pathologist Xiang-Yang Han discovered that Mycobacterium 
lepromatosis causes diffused lepromatous leprosy (DLL), the most severe form of 
leprosy. DLL is mostly found in Mexico and the Caribbean.9  
The mechanism of transmission for M. leprae is poorly understood. However the 
nasal mucosa respiratory tract is the most likely point of entry. Prolonged contact or 
overcrowding of leprosy patients with uninfected individuals will increase the risk of 
leprosy infection. The bacteria can survive outside of the body from 36 hours to 9 days. 
Skin transmission has never been proven.1 Recently, leprosy was found to be transmitted 
through infected needles used in tattooing, mainly in India.10 Direct transmission from 
mother to baby during pregnancy or childbirth is also possible.11 In the Old World, where 
leprosy was first known, it was not known to be a zoonotic disease. However, leprosy has 
since been found to be sustained in the armadillo population; hence, prolonged contact 
with infected armadillo can cause leprosy infection in humans,5,12 since the pathogen 
resides on the animal’s skin. 
 
1.1.4 Leprosy: Classification and Clinical Features 
Three main types of leprosy are known: lepromatous leprosy (LL), tuberculoid 
leprosy (TL), and an intermediate state (Fig. 29, Appendix). The initial stage of the 
disease (indeterminate cases) is easy to cure even if the clinical diagnosis is difficult. The 
intermediate states are classified as borderline lepromatous (BL) or borderline 
tuberculoid (BT). Both TL and BT are stable and rarely contagious. If the host’s immune 
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system is strong, this type of leprosy may resolve spontaneously. However both LL and 
BL can be dynamic, progressive, and infectious, and progression of the disease can cause 
formation of nodules and papules with marked, diffused infiltration of the skin. This type 
of leprosy involves more severe disability and nerve damage. The diagnosis of leprosy is 
based on: hypopigmentation with loss of sensation, thickened peripheral nerves, and/or 
acid-fast bacteria detected on skin smears or biopsy material.13 
Leprosy is curable by a combination of first-line drugs. First-line drugs include 
rifampicin (inhibits RNA synthesis), dapsone, and clofazimine (mechanisms are poorly 
known) (Fig. 30, Appendix). Second-line drugs (minocycline, ofloxacin (floroquinolone), 
and clarithromycin) are available if bacteria become resistant to first-line drugs. Although 
leprosy is curable with antibiotics and the disease is rare in United States with only 100-
200 new cases each year, there are still hundreds of thousands of new cases reported 
worldwide annually.12  
 
1.1.5 Leprosy Genomics and Pathogenesis 
Mycobacteria are commonly found in the soil and water, and many are non-
pathogenic to humans, whereas a few of them are pathogens to humans and animals 
(M. leprae, M. lepromatosis and M. tuberculosis). Mycobacteria are known for their slow 
growth with doubling times of approximately 24 hours for M. tuberculosis and 14 days 
for M. leprae. Hence, it is very difficult to culture M. leprae in vitro, and currently there 
is no method to do so; however, the genome of M. leprae has been completely 
sequenced.14 Phylogenetic studies of M. leprae and M. lepromatosis showed that they 
came from a common ancestor approximately ten million years ago. Before the 
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divergence, their ancestor had undergone a massive reductive evolution that caused 
inactivation of approximately forty percent of all the genes in its genome (~2000 genes) 
that are no longer required in highly specialized niches;14,15 the remaining genes are a 
minimal gene set necessary for survival, infection, and pathogenesis.  
 
1.2 Tuberculosis 
1.2.1 Definition of Tuberculosis 
Tuberculosis (TB) is an infectious disease that is mainly caused by Mycobacterium 
tuberculosis (MTB). It typically infects the lungs, resulting in chest pain, bloody sputum, 
and often death. MTB can also affect the brain and spine.16 Its route of transmission is 
through air droplets from the sputum from the infected lungs (Fig. 31, Appendix). The 
risk of transmission is based on the degree of exposure (proximity and time) and how 
vulnerable an exposed person is (people with weakened immune systems tend to be at 
increased risk of infection).17  	  
1.2.2 History of Tuberculosis 
TB is an ancient disease, documented in Egypt more than 5000 years ago, in India 
3300 years ago, and in China 2300 years ago.18 TB has plagued humankind throughout 
history; prior to antibiotics patients could not be cured. Even diagnosing TB was a 
challenge. Physicians developed different tests to confirm TB. The ancient Greeks 
developed tests to analyze what the tubercular patient coughed up; they had the patient 
spit into a copper vessel filled with seawater and watched the sputum’s behavior or they 
dripped the sputum on hot coals and smelled for “rotten meat”.7 
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Diagnosis methods improved in 1761 when Leopold Auenbrugger invented 
percussion. This method allowed a physician to put his ear to a patient’s chest, gently tap 
the chest, and listen. A dull vs. a hollow sound indicated that the lungs were not healthy 
and that the person might have TB. René Laënnec improved percussion by using a 
stethoscope.19 In 1895, Wilhelm Roentgen developed the use of X-rays, and this method 
is still in use today for early diagnosis of infected patients.20 
Since there was no cure for TB before the discovery of antibiotics, people who were 
diagnosed with TB would try everything they could think of to cure themselves, which 
included a lot of seemingly odd treatments, but ultimately the treatments that appeared to 
work were most likely boosting the immune system. Facilities opened where only people 
with TB could go to attempt to be cured. These sanatoria, usually located in the 
countryside or mountains,7 allowed patients to get plenty of fresh air, sun, rest, and 
nutritious food, all things now known to boost the immune system. An additional benefit 
was that they were isolated from uninfected people; they would stay at the sanatorium 
until they were cured or died from the disease.21 Unfortunately, sanatoria became very 
crowded and the number of people infected with TB greatly outnumbered those who 
could be admitted.  
The bacterium that causes TB was isolated and discovered by Robert Koch in 1882.7 
After isolating bacteria from the lungs of TB patients, he tried staining the cultures. It 
was good fortune that he used an old methylene blue dye contaminated with ammonia, 
which allowed the dye to enter the cells by destroying TB’s protective coat. In this way 
Koch confirmed that isolated stained rod microorganisms were the cause of TB.  
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In 1921, French scientists Albert Calmette and Camille Guérin developed a vaccine 
against TB, known as BCG (Bacillus Calmette-Guérin) vaccine.22 More recently, it has 
been discovered that the vaccine is only eighty percent effective in preventing TB in 
children, and not very effective in adults.23 
In 1944, Selman Waksman and Albert Schatz discovered streptomycin, the first 
antibiotic effective against TB.24, 25 This was a miracle drug, as it was the first truly 
effective cure for TB. Because of streptomycin’s great success, many antibiotics were 
developed in the 1940s and 1950s, the most notable being isoniazid and rifampin.18 There 
was a sharp decline in TB between 1953 and 1987, with the number of TB cases 
dropping by more than seventy percent in the United States due to the discovery and 
surge in antibiotics.7, 26 Unfortunately, resistance of TB to streptomycin started to develop 
within months of its discovery, and resistance to other antibiotics followed within years 
of their discovery. TB cases rose dramatically due to both resistance to antibiotics and the 
emergence of HIV-infections between the late 1980s and 1992.27 A novel program 
developed in the early 1990s, Directly Observed Therapy Short-Course (DOTS),27, 28 has 
become an effective treatment against TB and is still used today. This program is time 
consuming and expensive because it involves health care workers physically watching 
patients taking their TB medications. However, it works, and studies have shown that 
eighty percent of TB patients in Africa and India have been cured using DOTS.7 
 
1.2.3 Latent Infection of TB and MTB Life Cycle 
TB can exist in two different forms in the human body: as a latent infection or as an 
active infection. A latent infection of TB is shown in Fig. 31 (Appendix); MTB can be 
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found inside granulomas for years, and individuals show no symptoms of TB, as the 
immune system keeps the MTB in check and represses its multiplication and spread 
inside the body.  
The bacteria first enter the body by inhalation of droplets that contain MTB. When 
the bacterium reaches the alveoli of the lung, it is recognized and taken up by 
phagocytosis (macrophages). The macrophages then move to the surrounding tissue in 
the epithelial layer causing a local immune response. B-cells and T-cells quickly arrive 
trying to eliminate the bacteria, which causes the formation of a granuloma.29 The 
infected macrophages reside in the center of the granuloma that has ingested the MTB. 
As seen in Fig. 31 (Appendix) these infected cells are surrounded by other immune cells 
such as lymphocytes and other macrophages. These immune cells in granuloma 
eventually develop a fibrous material that envelops the mass of immune cells. This is its 
latent stage, if the bacteria stay dormant inside of the granuloma. Otherwise, the 
granuloma lose vasculature, causing cell death and rupture of the granulomas, thus 
allowing the bacteria to multiply and be released into the airways where it can now infect 
other people.30  
 
1.2.4 Active Infection of TB and Its Symptoms  
Patients with latent TB cannot transmit the disease to others, but it can become 
active (Fig. 31, Appendix) if the individual becomes immunocompromised: 
AIDS,29,30,32,33 age,31 malnutrition,34 and diabetes mellitus35 all suppress the immune 
system. Individuals with AIDS are 30 times more susceptible to becoming infected with 
TB. In active TB, MTB multiplies inside of the granuloma (Fig. 31, Appendix) and 
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causes the granuloma to rupture at which point the person infected will start to show 
symptoms of the disease: chest pain, weakness, unintentional weight loss, fever, and 
cough.36 Because many of TB symptoms are similar to those of other diseases, such as 
influenza or the common cold, it can be difficult to diagnose. The main telltale sign of 
active TB is the coughing up of blood, but by that point, TB is usually quite advanced.  
 
1.2.5 Mechanisms of Drug Action and Drug Resistance 
Despite the availability of the BCG vaccine and an effective DOTS program, TB has 
been the leading cause of death due to infectious disease throughout history, and has 
killed more than a billion people in the past two hundred years alone29 (Fig. 32, 
Appendix). Two main reasons for the increase in TB in more recent years and what 
makes it so difficult to eliminate are: the deadly synergy with the human 
immunodeficiency virus33 (HIV) and the development of drug resistant strains of TB.  
Genomic studies of various MTB strains show that there are three types of drug 
resistant strains of TB: multidrug-resistant TB (MDR-TB), extensively or extremely 
drug-resistant TB (XDR-TB), and totally drug-resistant TB (TDR-TB). MDR-TB is 
resistant to the two most commonly used first-line drugs, isoniazid and rifampin, in the 
current five-drug regimen (Fig. 30, Appendix). More than eighty percent of MDR-TB 
patients died in the late 1980s and early 1990s in North America and Europe.37 MDR-TB 
is treated with second-line drugs (capreomycin, amikacin, and kanamycin) (Fig. 30, 
Appendix), which are toxic with dangerous side effects. XDR-TB is resistant to both 
isoniazid and rifampin with any fluoroquinolone, and at least one of the second-line 
drugs.38 With resistance to so many antibiotics, treatment is challenging. TDR-TB is 
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resistance to all currently available antibiotics. Since there is no treatment, active  
TDR-TB is always lethal. So far, there have been only a few cases of TDR-TB. However 
if TDR-TB spreads, we could be facing a new pandemic of untreatable TB.39 
 
1.2.6 Discovery and Characterization of Novel Potential Antibiotic Targets 
As can be seen, especially for MTB, antibiotic drug resistance is a serious problem. 
Thus, it is essential to discover novel potential antibiotic targets and to develop drugs 
against these targets. Our research pertains to the discovery and characterization of new 
potential drug targets in the important human pathogens M. leprae and MTB. By 
studying enzymes of a particular protein superfamily, we increase the probability of 
determining the activity of these enzymes. We have chosen to focus on the Nudix 
hydrolases, as discussed below.  
 
1.3 Nudix Hydrolases 
1.3.1 Definition 
The Nudix hydrolases are a superfamily of enzymes found in all three domains of 
life: archaea, prokaryotes, and eukaryotes. They hydrolyze substrates with the general 
structure of a nucleoside diphosphate linked to some moiety, X (Nudix) and almost 
always yield NMP and X-P as products. The general reaction is: 
  𝐍− 𝐏− 𝐏− 𝐗  +   𝐇𝟐𝐎   →   𝐍𝐌𝐏  +   𝐗− 𝐏	  	   	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  Eq. 1 
Nudix hydrolase superfamily enzymes are typically small single domain proteins 
(16-21 kDa, 130-200 residues). They are identified by the highly conserved 23-amino 
acid signature sequence (Nudix box), GX5EX7REUXEEXGU, where U is a bulky 
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aliphatic amino acid (I, L, or V), and X is any amino acid. The consensus sequence 
creates a loop-helix-loop structural motif, and the glutamates in the core of the motif 
(REUXEE), play an essential role in binding of divalent cations (usually Mg2+).40 
The first characterized enzyme of the Nudix hydrolase superfamily was MutT from 
Escherichia coli (E. coli). Disruption of mutT causes a 1,000-10,000 fold increase in the 
spontaneous mutation frequency due to AT:CG transversions.41 One hypothesis for how 
MutT prevents mutations is its hydrolysis of the reactive oxygen species 8-oxo-dGTP to 
prevent its incorporation into DNA. Initially scientists thought this might be an 
antimutator family, but it was quickly discovered that only MutT and its orthologs 
prevent mutations.  
 
1.3.2 Substrate Specificity and Enzyme Function 
The Nudix hydrolase superfamily is composed of enzymes with a wide array of 
substrate specificities. Nudix hydrolases recognize and cleave a specific group of 
substrates such as: (d)NTPs (Eq 2-4), nucleotide sugars (Eq 5-7), diadenosine 
polyphosphates (ApnA) (Eq 8-10), or coenzyme A (Eq 11). However, some Nudix 
hydrolases can have broad substrate specificity; YZGD has the broadest substrate 
specificity of all the Nudix hydrolases that have been characterized, hydrolyzing ADP-x, 
CDP-x, and TDP-x substrates equally well, and even hydrolyzing UDP-x and GDP-x to a 
lesser extent. The only Nudix substrates that YZGD does not cleave are (d)NTPs, 
ApnA’s, and coenzyme A.42  
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                     𝟖𝐨𝐱𝐨 𝐝𝐆𝐓𝐏  +   𝐇𝟐𝐎  →    𝟖𝐨𝐱𝐨 𝐝𝐆𝐌𝐏  +   𝐏𝐏𝐢       Eq. 2                                                         𝐝𝐀𝐓𝐏  +   𝐇𝟐𝐎  →   𝐝𝐀𝐌𝐏  +   𝐏𝐏𝐢        Eq. 3                                                     𝐂𝐓𝐏  +   𝐇𝟐𝐎    →   𝐂𝐌𝐏      +   𝐏𝐏𝐢        Eq. 4         𝐀𝐃𝐏− 𝐫𝐢𝐛𝐨𝐬𝐞  +   𝐇𝟐𝐎   →   𝐀𝐌𝐏    +   𝐫𝐢𝐛𝐨𝐬𝐞− 𝟓− 𝐏            Eq. 5 𝐆𝐃𝐏−𝐦𝐚𝐧𝐧𝐨𝐬𝐞+ 𝐇𝟐𝐎 →   𝐆𝐃𝐏      +   𝐦𝐚𝐧𝐧𝐨𝐬𝐞       Eq. 6   𝐔𝐃𝐏− 𝐠𝐥𝐮𝐜𝐨𝐬𝐞    + 𝐇𝟐𝐎   →   𝐔𝐌𝐏  +   𝐠𝐥𝐮𝐜𝐨𝐬𝐞− 𝟏− 𝐏       Eq. 7                                             𝐀𝐩𝟒𝐀  + 𝐇𝟐𝐎   →   𝐀𝐌𝐏  +   𝐀𝐓𝐏        Eq. 8                                               𝐀𝐩𝟓𝐀+ 𝐇𝟐𝐎   →   𝐀𝐃𝐏  +   𝐀𝐓𝐏        Eq. 9                                               𝐀𝐩𝟔𝐀+ 𝐇𝟐𝐎 →   𝐀𝐓𝐏    +   𝐀𝐓𝐏                  Eq. 10                                                                     𝐂𝐨𝐀+𝐇𝟐𝐎  →   𝟑′,𝟓′−𝐀𝐃𝐏  +   𝟒′−𝐩𝐡𝐨𝐬𝐩𝐡𝐨𝐩𝐚𝐧𝐭𝐞𝐭𝐡𝐞𝐢𝐧𝐞    Eq. 11	  
 
Due to their versatile substrate preferences, Nudix hydrolases are suggested to be 
involved in a variety of different metabolic pathways. Bessman defined the Nudix 
hydrolases as having a common “housecleaning” function, “cleansing potentially 
hazardous materials, or preventing the unbalanced accumulation of normal 
metabolites.”41 
 
1.3.3 The Nudix Hydrolases from MTB and M. leprae 
There are eleven potential Nudix hydrolases in MTB, as determined by their Nudix 
signature sequence. The O’Handley lab has been systematically cloning, expressing, and 
characterizing these enzymes. Ten have been cloned, six express to produce obvious 
bands of overexpressed protein on SDS PAGE, but the enzymatic activity has only been 
determined for four: two ApnAases, one (d)CTPase, and one ADP-ribose hydrolase, (see 
Table I). Five of the MTB Nudix hydrolases have highly conserved homologs in 
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M. leprae with E values of E-107 to E-144, and five have homologs in M. leprae with E 
values of E-2 to E-10, (see Table II). 
Note the two diadenosine polyphosphatases in MTB and the two corresponding 
orthologs in M. leprae (Fig. 2 and 3). If an organism has two proteins with similar 
activity and function, this is an indication that the activity is probably important for the 
organism’s survival. M. leprae has gone through significant reductive evolution;14, 43 if a 
protein / protein function exists in M. leprae, this is another indication that the activity is 
probably important for the M. leprae’s survival, as it has jettisoned many proteins and 
activities through reductive evolution.  
 
Table I: Nudix hydrolases from MTB Protein	   Nudix	  Sequence	   Cloned	  	   Expressed	   Substrate(s)	  	  Rv2985	   GKVDPGETAPVGAVREILEETGH +	   +	   ApnA	  Rv3908	   GHEILGETAEQTAIREVAEERGI +	   +	   ApnA	  Rv1160	   GKVAAGETERAALARELAEELGL +	   +	   (d)	  CTP	  Rv1700	   GLLDVAGEPPHLTAARELREEVGL +	   +	   ADP-­‐ribose	  Rv1593	   GRLRNDEDMTSSVRRQLAEKVDL +	   +	   -­‐	  Rv3733	   GEYTGGEDPWLAARREFSEEIGL +	   +	   -­‐	  Rv413	   GARDSHETPEQTAVRESSEEAGL +	   -­‐	   -­‐	  Rv1745	   GHPLPGESLPGAIRRRLAAELGL +	   -­‐	   -­‐	  Rv3199	   GQVRPGERLAQAAARELAEETGL +	   -­‐	   -­‐	  Rv3672	   GCCPADDGPVATALREANEETGI +	   -­‐	   -­‐	  Rv2609	   GQVRPGERLAQAAARELAEETGL -­‐	   -­‐	   -­‐	  
 
 
 
 
 
 
 
	   15	  
 
 
Table II: Nudix hydrolases from M. leprae 
MTB Protein M. leprae Orthologa Predicted Substrate(s)b 
Rv2985 1 × E-130 ApnA 
Rv3908 1 × E-107 ApnA 
Rv1160 2 × E-4 (d)CTP 
Rv1700 4 × E-5  ADPribose 
Rv1593 1 × E-114 GDPmannose 
Rv3733 3 × E-2  
Rv413 9 × E-5 (d)CTP 
Rv1745   
Rv3199 3 × E-3 NADH 
Rv3672 1 × E-114 CoA 
Rv2609 1 × E-144  
  a: “the Expectation value represents the number of different alignments with scores 
equivalent to or better than S that is expected to occur in a database search by chance. 
The lower the E value, the more significant the score and the alignment.”44  
 b: These predictions came from the entrez report pages for the MTB homologs. 	  
1.3.4 Diadenosine Polyphosphatases 	  Diadenosine polyphosphatases, ApnAases where n≥4, are Nudix hydrolases found in 
bacteria, plants, and animals that cleave diadenosine polyphosphates (ApnA) into two 
products as depicted in equations 8-10 in section 1.3.2. Substitution always occurs on the 
fourth phosphate δP (for n≥4) with ATP as the leaving group. The general role of 
diadenosine polyphosphatases is to regulate the cellular levels of diadenosine 
polyphosphate signaling molecules.  
Phenotype studies of knockout mutants showed that diadenosine polyphosphatases 
are involved in the invasion process of human host cells by various pathogens. The 
Ap4Aases from Bartonella bacilliformis (the cause of Oroya fever) and Helicobacter 
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pylori (a cause of stomach ulcers) are involved in and required for the pathogens’ ability 
to invade human erythrocytes45 and the gastric system,46 respectively. ApnAase was 
determined to be a virulence factor in Legionella pheumophila.47 ApnAase from 
Rickettsia prowazekii, the causative agent of epidemic typhus, was found to be involved 
in invasion of the host’s endothelia cells.48  
Diadenosine polyphosphatases are also found in MTB (Rv2985 and Rv3908) and 
M. leprae (Ml1682 and Ml2698). Rv2985 has been cloned, expressed, purified, and 
characterized previously by others in the O’Handley lab, therefore the main focus of this 
thesis project is on Rv3908 and the two orthologs from M. leprae. If these enzymes are 
involved in invasion and thus in virulence, similar to the orthologs discussed in the above 
paragraph, these enzymes could be novel antibiotic targets in MTB and M. leprae. 
Alignments of these ApnAases are shown in Fig. 1-3, where the following amino 
acid groupings are designated as similar amino acids: A/G, I/L/V, S/T, F/W/Y, D/E, 
K/R/H, and N/Q. 
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Figure 1:	  Clustal alignment of Nudix hydrolase diadenosine polyphosphatases. Identical 
amino acids are denoted by “*” and similar amino acids are denoted by “•”.  
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Figure 2: Clustal alignment of ApnAase/mRNA decapping orthologs Rv2985 in 
M. tuberculosis and Ml1682 in M. leprae. 72% of the amino acids are identical and 
denoted by “*” while 76% of the amino acids are similar and denoted by “•”. 
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Figure 3: Clustal alignment of ApnAase/mRNA decapping orthologs Rv3908 in 
M. tuberculosis and Ml2698 in M. leprae. 79% of the amino acids are identical and 
denoted by “*” while 83% of the amino acids are similar and denoted by “•”. 
 
1.3.5 mRNA Decapping Enzyme 
In both prokaryotes and eukaryotes, DNA is transcribed into messenger RNA 
(mRNA) before it is translated into protein. In eukaryotes, the transcribed mRNA is 
processed prior to translation. mRNA processing includes the addition of a 5’ 7-methyl 
guanosine cap (Me7Gp3), addition of a poly-A tail at the 3’ end, and mRNA splicing to 
remove non-coding introns. The Me7Gp3 capping protects the mRNA chain from 
degradation by nucleases. Hence, the first step of degradation of mRNA is to remove the 
methylated cap (decapping).  
Degradation of mRNA is an essential process in eukaryotic cells to control gene 
expression. The mRNA decapping enzymes remove the methylated cap to expose a 
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monophosphorylated 5’ end on the mRNA.49 These eukaryotic enzymes that 
hydrolytically decap the 5’ end of capped mRNA were found to contain the 23-residue 
Nudix signature sequence. The catalytic reaction is shown below (eq. 12).50                                         𝐌𝐞𝟕𝐆𝐩𝟑 − 𝐑𝐍𝐀+ 𝐇𝟐𝐎 → 𝐌𝐞𝟕𝐆𝐃𝐏+ 𝐩− 𝐑𝐍𝐀       Eq. 12 
More interestingly, several prokaryotic diadenosine polyphosphatases have recently 
been discovered to also act as mRNA decapping enzymes to remove pyrophosphate from 
the 5’ termini of mRNAs. Thus, these activities suggest both ApnA’s and mRNAs are 
biologically relevant substrates for these ApnAase mRNA decapping enzymes, and 
currently it is not known which activity or if both activities are involved in the invasion 
process.51 
 
1.3.6 Rv2985 ApnAase from MTB 
Rv2985 has been previously cloned, expressed, purified, and characterized in the 
O’Handley lab. The gene rv2985 was successfully cloned into the plasmid pET11b to 
create pETrv2985, and successfully subcloned into the plasmid pET19b to create 
pET19rv2985, which placed a His•Tag at the N-terminal end of the expressed protein. 
Each was transformed into Escherichia coli (E. coli) DH5α for storage and E. coli 
BLR(DE3) for expression.  
Untagged Rv2985 protein was purified and characterized; however, for easier 
purification and higher yield of purified protein, Rv2985(HT) was also purified and 
characterized. Rv2985(HT) was expressed at 15 °C in E. coli BLR(DE3) using isopropyl 
β-D-1-thiogalactopyranoside (IPTG) to induce protein production. The cells were 
	   21	  
harvested and ruptured by sonication. The sonicated supernatant was purified via Ni2+ 
affinity chromatography followed by size exclusion chromatography (see Fig. 4).  
Both the untagged protein and the His•Tagged protein gave identical results upon 
characterization. Rv2985 is a diadenosine polyphosphatase with maximal activity on 
Ap6A (see Table III). Optimal activity was achieved in the pH range of 8.5-9.0 and in the 
presence of 5 mM Mg2+. Zn2+, Mn2+, and Co2+ yielded 21%, 6%, and 4% as much 
activity (as with 5 mM Mg2+), respectively, while Ca2+ yielded no activity. Rv2985 
always attacks the fourth phosphorous from one of the adenosines to yield ATP and 
either AMP, ADP, or another ATP depending on whether the substrate is Ap4A, Ap5A, or 
Ap6A, respectively (see Fig. 5). Rv2985 has also been determined to be a mRNA 
decapping enzyme by our collaborators, Sandra Gabelli and Mario Amzel at Johns 
Hopkins University (see Fig. 6).  	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Figure 4: Expression and purification of Rv2985(HT). Lane1: sonicated supernatant; 
Lanes 2&3: purified Rv2985(HT) after Ni2+ affinity chromatography, dialysis, and 
concentration; Lane 4: Molecular Weight Markers (MWMs). (Unpublished results, 
O’Handley et al.) 	  
Table III: Substrate Specificity and Kinetics of Rv2985(HT). 
Substrate kcat (s-1) Km (M) kcat/Km (M-1s-1) 
Ap6A 74.41 1.78×10-3 4.18×104 
Ap5A 27.09 1.02×10-3 2.66×104 
Ap4A 31.81 1.22×10-3 2.61×104 
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A. 	  
	  
B. 	  
	  
Figure 5: Reactions of the ApnA’s with Rv2985. A. HPLC chromatograms showed that 
for the substrates Ap4A, Ap5A, and Ap6A, the products were ATP and either AMP, ADP, 
or ATP, respectively. ATP is always one of the products. B. 31P NMR showed the same 
products as HPLC. Additionally, when the reactions were carried out in H218O, the 18O 
was transferred to AMP (for the reaction with Ap4A) and ADP (for the reaction with 
Ap5A) indicating that attack by H2O is always at the fourth phosphorus from one of the 
adenosines. (Unpublished results, O’Handley et al.) 	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Figure 6: mRNA decapping assay. Rv2985 removed the 5’ 32P-labeled end of 
triphosphate capped mRNA releasing radioactive pyrophosphate. Nudt1 (Human mutT 8-
oxo-dGTPase) was used as a negative control as it does not decap mRNA. (Unpublished 
results, Gabelli and Amzel, in collaboration) 
 
1.4 Methodology 
1.4.1 Subcloning 
For this thesis, genes were subcloned from pET11b into pET19b. Both plasmids 
contain a T7 lac promoter for overexpression. The T7 lac promoter has a lac operator 
sequence situated downstream from the promoter region.52 The lac repressor binds to this 
region and inhibits transcription, thus reducing basal expression. A similar lac promoter 
controls transcription of the T7 RNA polymerase that is encoded in (DE3) strains of 
E. coli and both are inducible by IPTG. The structure of IPTG is similar to allolactose, a 
natural inducer for the lac promoter. pET19b also contains a sequence that codes for a 
string of 10 histidines to create a His•Tag on the N-terminal end of the protein.53 A 
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schematic of the pET19b plasmid is shown in Fig. 7. The pET plasmids contain NdeI and 
BamHI restriction sites, which can be utilized for subcloning as depicted in Fig. 8.  
 
  
Figure 7: pET19b containing a T7 lac promoter, a His•Tag coding sequence, EcoRV, 
NdeI, and BamHI restriction sites. 
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Figure 8: ml1682 subcloned into pET19b. ml2698 and rv3908 were subcloned identically. 
 
1.4.2 Overexpression and Purification 
The procedure for overexpression and purification of protein is shown on Fig. 9. 
Proteins are overexpressed by induction with IPTG. Sonication lyses cells by high energy 
sound waves. Ni2+ affinity chromatography resin binds His•Tagged proteins tightly 
through the imidazole side chains of histidine forming complexes with the Ni2+ of the 
column, allowing all other proteins to flow through the column. Increasing concentration 
of imidazole allows the imidazole to outcompete with the His•Tagged proteins for the 
Ni2+ of the resin. (Fig. 33, Appendix). 
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Figure 9: Schematic for Ml1682(HT), Ml2698(HT), and Rv3908(HT) expression and 
purification.  
 
Dialysis is used to remove the free imidazole from the His•tagged protein sample. 
Dialysis separates small molecules from macromolecules based on their molecular size. 
The membrane of the dialysis cassette allows small molecules such as imidazole to 
diffuse through the membrane, retaining the large macromolecules in the cassette. 
Concurrently, the new buffer outside the dialysis cassette can diffuse into the cassette 
through the membrane.  
 
1.4.3 Solubilization Experiments 
Prokaryotic expression systems, especially E. coli, have been exploited for the 
production of a wide range of recombinant proteins in the last three decades. E. coli cells 
are convenient hosts for the expression of foreign proteins because they have a short 
doubling growth rate, require inexpensive growth conditions, and offer a simple process 
to scale up. However, two main disadvantages of using E. coli cells are: expression can 
be low due to rare codon usage and they can produce inactive insoluble protein due to the 
formation of inclusion bodies. A number of current strategies have been developed to aid 
in expression of soluble protein.  
Protein expression at low temperatures slows down cell growth and protein 
expression allowing more time for the protein to fold, increasing the probability of proper 
folding.54 A change in media composition is another technique to obtain soluble protein. 
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Cells grow slower in M9 minimal media,55 thus as with lower temperatures, the proteins 
express and fold more slowly. The addition of glycylglycine into rich media enhances 
production of soluble proteins by also slowing down cell growth and allowing more time 
for the expressed proteins to fold properly.56 Co-expression with the chaperone  
GroEL-GroES can increase solubility of expressed proteins, because molecular 
chaperones assist the folding of polypeptides.57, 58 
Most amino acids are encoded by more than one codon and each organism has a 
codon bias. When the genes that encode foreign proteins contain “rare” codons for 
E. coli, E. coli does not produce as much aminoacyl tRNA for that codon, leading to 
lower translation rates and thus lower protein expression. The E. coli strain Rosetta(DE3) 
overexpresses these “rare” tRNAs, and thus allows for more efficient translation, 
resulting in better expression and the production of more soluble protein.59  
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2. Materials and Methods 
2.1 Subcloning of ml1682, ml2698, and rv3908 into pET19b 
2.1.1 Plasmid Midipreps 
Prior to this work, others in the O’Handley lab cloned ml1682, ml2698, and rv3908 
into pET11b to create pETml1682, pETml2698, and pETrv3908, respectively. pET19b is 
a plasmid containing a nucleotide sequence that codes for a string of 10 histidines at the 
N-terminal end of a protein. E.coli DH5α cells containing pET19b, pETml1682, 
pETml2698, or pETrv3908 were each grown in separate 50 mL Luria-Bertani (LB) media 
with 0.1 mg/mL ampicillin at 37 °C with shaking for approximately 16 hours. The cells 
were harvested by centrifugation at 14,000 RCF (relative centrifugal force) for 2 minutes 
at room temperature. Harvested cells were treated with 100 µL solution I containing 
50 mM glucose, 25 mM Tri•HCl (pH 8.0), and 10 mM EDTA to resuspend the cells. 
200 µL solution II containing 0.2 M sodium hydroxide and 1% SDS was added to rupture 
the cells. 150 µL solution III containing 3 M potassium and 5 M acetate was used to 
precipitate E.coli chromosomal DNA, leaving plasmid DNA in solution.  
DNase-free bovine pancreatic RNase A (Sigma) in TE buffer (10 mM Tris•HCl (pH 8.0), 
1 mM EDTA) was added to the supernatant for a final concentration of 50 µg/mL 
RNase A, and this was incubated at 37 °C for 30 minutes. Proteins were denatured and 
removed using phenol:chloroform (1:1) and chloroform extractions. The plasmid DNA 
was precipitated with 70% ethanol by freezing the solution and centrifugation at 
14,000 RCF at 4 °C for 30 minutes. The pellet was washed with ice-cold 70% ethanol 
and dried using vacuum centrifugation. The pellet was dissolved in cold sterile water. 
The plasmid DNA was treated with 13% polyethylene glycol (PEG) and 5 M sodium 
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chloride solution on ice for approximately 18 hours to remove tRNAs from the sample. 
The sample was centrifuged at 14,000 RCF at 4 °C for 30 minutes, and the pellet 
containing the plasmid was washed with 70% ice-cold ethanol. Pellets were resuspended 
in cold sterile water. The DNA concentration was determined at 260 nm on a UV-Vis 
spectrophotometer. The plasmids were analyzed further by 0.7% agarose gel 
electrophoresis.   
 
2.1.2 Restriction Enzyme Digests and Purification of Digested Gene and Digested 
Plasmid  
The restriction enzymes, NdeI and BamHI-HF endonucleases (New England 
Biolabs) were used in a double-digest to excise the ml1682, ml2698, or rv3908 genes 
from the pETml1682, pETml2698, or pETrv3908 plasmids, respectively. The pET19b 
plasmid was also digested with the same restriction enzymes. The efficiency of the 
digests was verified by also treating pET19b plasmid with each of the restriction enzymes 
separately. Samples were analyzed by 0.7% agarose gel electrophoresis. The digests were 
incubated at 37 °C for 2 hours total; NdeI endonuclease was added to each sample every 
30 minutes. The double digested plasmids were purified from a 0.7% agarose gel (run for 
90 minutes and stained with ethidium bromide). Bands on the gel containing the digested 
pET19b and the excised genes were cut out and purified using a gene-clean kit (MP 
Biomedicals) following the kit’s protocol. The purified digested pET19b plasmid and 
purified excised genes were analyzed by agarose gel electrophoresis.   
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2.1.3 Ligations 
Each of the three genes (ml1682, ml2698, and rv3908) was ligated separately into 
digested pET19b. A 1:1 ratio of plasmid:gene is theoretically ideal so ligations were set 
up spanning a range around this 1:1 ratio (see Tables IV-VI). Ligations contained 
digested plasmid, digested gene, ligase buffer, and ligase (Invitrogen), and were 
incubated at 15 °C for approximately 24 hours. 
 
Table IV: Ligation of ml1682 into pET19b. 
Ligation 
Mixture 
pET19b:ml1682 pET19ba 
(ng) 
ml1682b 
(ng) 
Number of 
Coloniesc 
A - 75 0 ~83 
B 1:0.5 75 7.0 ~362 
C 1:1 75 13.5 ~256 
D 1:1.67 75 22.5 ~94 
a : pET19b is 5705 basepairs 
b : ml1682 is 993 basepairs 
c: 50 mL transformation cell cultures plated onto plates containing LB-Ampicillin  
 
Table V: Ligation of ml2698 into pET19b.  	  	  
 
 
 
 
a : pET19b is 5705 basepairs 
b : ml1682 is 747 basepairs 
c : 50 mL transformation cell cultures plated onto plates containing LB-Ampicillin  
 
 
 
 
 
 
Ligation 
Mixture 
pET19b:ml2698 pET19ba 
(ng) 
ml2698b 
(ng) 
Number of 
Coloniesc 
A - 75 0 7 
B 1 : 0.5 75 5.1 5 
C 1 : 1.0 75 10.2 12 
D 1: 2.2 75 22.4 9 
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Table VI: Ligation of rv3908 into pET19b.	   	  
 
 
 
 
 
 
a : the yield of purified excised gene was too low for a 1:1 ratio. 
b :pET19b is 5705 basepairs 
c : rv3908 is 747 basepairs 
d : 50 mL transformation cell cultures plated onto plates containing LB-Ampicillin  	  
2.1.4 Transformations 
5 µL of each Ligation mixture (A-D) were added to 50 µL E.coli DH5α (Novagen) 
competent cells separately. pUC19 was added to the DH5α cells as a positive 
transformation control. Samples were incubated on ice for 30 minutes, heat shocked in a 
37 °C water bath for 25 seconds, and immediately placed back on ice for at least 
2 minutes. 1 mL of LB media was added to each of the samples and were incubated at 
37 °C for 1 hour with mixing every ~10 minutes. The cells were plated onto LB plates 
containing 0.1 mg/mL ampicillin and incubated at 37 °C for approximately 16 hours. 
Colonies were selected to analyze for the successful subcloning of pET19ml1682, 
pET19ml2698, or pET19rv3908. Colonies containing pET19ml1682, pET19ml2698, or 
pET19rv3908 were streaked out to single colonies and cell cultures were grown in LB 
media containing 0.1 mg/mL ampicillin at 37 °C until ~1.0-1.5 ODs (A600) from these 
single colonies. Freezer stocks of E. coli DH5α containing either pET19ml1682, 
pET19ml2698, or pET19rv3908 were made using these cell cultures and glycerol and 
stored at -80 °C. 
Ligation 
Mixture 
pET19b:rv3908a pET19bb 
(ng) 
rv3908c  
(ng) 
Number of 
Coloniesd 
A - 75 0 88 
B 1 : 0.15 75 1.5 53 
C 1 : 0.30 75 3.0 20 
D 1: 0.69 75 6.8 4 
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2.1.5 Plasmid Minipreps 
12-24 different cultures containing a single colony from plates B-D (Table I-III) 
were grown separately in 5 mL LB media containing 0.1 mg/mL ampicillin at 37 °C with 
shaking for approximately 16 hours. The cells were harvested by centrifugation at 
14,000 RCF at 4 °C for 2 minutes. Harvested cells were resuspended with solution I, 
ruptured with solution II, and E. coli chromosomal DNA was precipitated with solution 
III (as above in the midiprep procedure). Phenol:chloroform (1:1) followed by 
chloroform extractions were performed (as above). The plasmid DNA was precipitated 
with 70% ethanol by freezing and centrifuging (as above). The pellets were rinsed with 
70% ice-cold ethanol, dried by vacuum centrifugation, and resuspended in sterile TE 
buffer (10 mM Tris•HCl (pH 8.0), 1 mM EDTA) containing 20 µg/mL DNase-free 
bovine pancreatic RNase A (Sigma). The plasmids were analyzed by 0.7% agarose gel 
electrophoresis; the size of the purified plasmids were compared to purified pET19b to 
determine if they potentially contained the gene of interest. 
 
2.1.6 Verification of Recombinant Plasmids 
To confirm that the isolated purified plasmids were recombinant pET19ml1682 (or 
pET19ml2698 or pET19rv3908), two restriction enzyme digestions were carried out. 
First, 8 µL of purified plasmids were digested with 1 µL each of NdeI and BamHI-HF 
endonucleases (NEB). Second, 8 µL purified plasmids were digested with 2 µL EcoRV 
endonuclease (NEB). The first method would excise the genes from the plasmid. The 
second method would cut the plasmids in two locations to yield a 4229 bp fragment and a 
fragment of 1488 bp for pET19b or larger if a gene was within the fragment. Digestions 
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were carried out at 37 °C for one hour. All digestions were verified by agarose gel 
electrophoresis. 
E.coli BLR(DE3) (Novagen) competent cells were transformed with purified 
pET19ml1682 (or pET19ml2698 or pET19rv3908). The transformed cells were plated 
onto plates containing LB and 0.1 mg/mL ampicillin. Colonies were streaked to single 
colonies. E. coli BLR(DE3) containing either pET19ml1682 (or pET19ml2698 or 
pET19rv3908) were used to produce cell cultures by incubating them in LB media 
containing 0.1 mg/mL ampicillin at 37 °C until 1.0 -1.5 OD (A600). Freezer stocks were 
made from these cell cultures and glycerol and stored at -80 °C. 	  
2.2 Overexpression and Purification of the Ml1682(HT), Ml2698(HT), and 
Rv3908(HT) Proteins 
2.2.1 100 mL Overexpression of Ml1682(HT) in E.coli BLR(DE3) at 37 °C 
An inoculum of pET19ml1682 in E.coli BLR(DE3) was made by adding a scraping 
of the freezer stock to 7.5 mL LB media containing 0.1 mg/mL ampicillin. The cells were 
grown at 37 °C with shaking until it reached ~1.0-1.5 OD (A600). 5 mL of inoculum was 
added to prewarmed 100 mL LB, containing 0.1 mg/mL ampicillin, and incubated at 
37 °C with shaking. The cell density was analyzed every 30 minutes until it reached an 
OD of 0.8 at A600 using UV-Vis spectrophotometry.  The culture was induced with 1 mM 
IPTG. Prior to induction, 1.5 mL culture was harvested and its pellet was labeled as time 
point 0 (TP=0) and stored at -80 °C for protein gel analysis. The induced cells were 
incubated at 37 °C with shaking for an additional 3 hours. Every 30 minutes, cell density 
was determined at A600 and every hour, 1.5 mL of culture was harvested; pellets were 
labeled as TP=1, 2, or 3 for 1, 2, or 3 hour(s) after induction, respectively, and were 
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stored at -80 °C. After 3 hours, the cells were harvested by centrifugation at 3,000 RCF at 
4 °C for 15 minutes. The pellet was suspended with ~20 mL buffered saline (50 mM 
Tris•HCl (pH 7.5), 86 mM NaCl, 67 mM KCl). The suspension was centrifuged at 3,000 
RCF at 4 °C for 15 minutes, and the pellet was rinsed with ~20 mL buffered saline. The 
final pellet was stored at -80 °C.  
 
2.2.2 100 mL Overexpression of Ml1682(HT), Ml2698(HT), and Rv3908(HT) in E.coli 
BLR(DE3) at 15 °C 
Inoculums of either pET19ml1682, pET19ml2698, or pET19rv3908 in E. coli 
BLR(DE3) were made by adding a scraping of the freezer stock to 7.5 mL LB media 
containing 0.1 mg/mL ampicillin. The cells were grown at 37 °C with shaking until it 
reached ~1.0-1.5 OD (A600). 5 mL of inoculum was added to prewarmed 100 mL LB, 
containing 0.1 mg/mL ampicillin, and incubated at 37 °C with shaking. The cell density 
was analyzed every 30 minutes until it reached an OD of ~0.3 at A600, at which point the 
cultures were incubated at 15 °C with shaking to an OD of ~0.6. Once the cell density 
reached ~0.6 OD, the cultures were induced with 1 mM IPTG. Prior to induction, 1.5 mL 
culture was harvested and its pellet was labeled TP=0 and stored at 
-80 °C. The induced cells were incubated at 15 °C with shaking for an additional 
22-24 hours. After 22-24 hours, 1.5 mL culture was harvested (TP=22-24). The rest of 
the culture was harvested by centrifugation at 3,000 RCF at 4 °C for 15 minutes. The 
pellets were resuspended in cold buffered saline (50 mM Tris•HCl (pH 7.5), 86 mM 
NaCl, 67 mM KCl), recentrifuged at 3,000 RCF at 4 °C for 15 minutes, and the pellets 
were rinsed with cold buffered saline. The final pellets were stored at -80 °C.  
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2.2.3 2L Overexpression of Ml1682(HT), Ml2698(HT) and Rv3908(HT) in E.coli 
BLR(DE3) at 15 °C 
Inoculums of either pET19ml1682, pET19ml2698, or pET19rv3908 in E. coli 
BLR(DE3) were made by adding a scraping of the freezer stock to 7.5 mL LB media 
containing 0.1 mg/mL ampicillin. The cells were grown at 37 °C with shaking until it 
reached ~1.0-1.5 OD (A600). 5 mL of inoculum was added to prewarmed 100 mL LB, 
containing 0.1 mg/mL ampicillin, and incubated at 37 °C with shaking to a cell density of 
~1 OD (A600). To each of two 1 L LB media containing 0.1 mg/mL ampicillin, 40 mL of 
this inoculum was added. The cell density was analyzed every 30 minutes until it reached 
an OD of ~0.3 at A600, at which point the cultures were incubated at 15 °C with shaking 
to an OD of ~0.6. Once the cell density reached ~0.6 OD, the cultures were each induced 
with 1 mM IPTG. Prior to induction, 1.5 mL of culture was harvested and its pellet was 
labeled TP=0 and stored at -80 °C. The induced cells were incubated at 15 °C with 
shaking for an additional 22-24 hours. After 22-24 hours, 1.5 mL culture was harvested 
(TP=22-24). The rest of the culture was harvested by centrifugation at 3,000 RCF at 4 °C 
for 15 minutes. The pellets were resuspended in cold buffered saline (50 mM Tris•HCl 
(pH 7.5), 86 mM NaCl, 67 mM KCl), recentrifuged at 3,000 RCF at 4 °C for 15 minutes, 
and the pellets were rinsed with cold buffered saline. The final pellets were stored at -80 
°C.  
 
2.2.4 Sonication 
The pellets from the 100 mL overexpression cultures were resuspended in 1 mL 
20 mM Tris•HCl (pH 8.0) while the pellets from the 2 L overexpression cultures were 
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resuspended in 2 volumes (by weight) 20 mM Tris•HCl (pH 8.0). The suspended cells 
were placed back at -80 °C for at least one hour to assist in cell lysis. 50 µl suspensions 
were labeled as whole cell crude extract and saved for SDS PAGE analysis. Cells were 
lysed by sonication using a Branson sonicator (output of 6.5 and 50% duty cycle), in 15-
second intervals for a total of 5 minutes. Sonicated samples were centrifuged at 
14,000 RCF for 5 minutes (100 mL culture) or 10,000 RCF for 30 minutes (2 L culture). 
The supernatants were separated from the pellets, and labeled as sonicated supernatant or 
sonicated pellet, respectively. Pellets were resuspended in 1 mL (100 mL culture) or 
2 volumes (2 L culture) of 20 mM Tris•HCl (pH 8.0). All fractions (whole cell crude 
extract, sonicated supernatant, and sonicated pellet) were stored at -80 °C. 
 
2.2.5 SDS-PAGE Analysis  
All time points (TP=0, 1, 2, or 3 for overexpression at 37 °C; TP=0 or ~22-24 for 
overexpression at 15 °C) were resuspended in H2O (100 µL per OD). Each whole cell 
crude extract, sonicated supernatant, and sonicated pellet was diluted to 0.1x with 20 mM 
Tris•HCl (pH 8.0). 5 µL of each time point and 0.1x sample, 10 µL 20 mM Tris•HCl 
(pH 8.0), and 5 µL 4x protein loading buffer (200 mM Tris•HCl (pH 6.8), 40% glycerol, 
8% SDS, 400 mM DTT, and 0.08% bromophenol blue dye) were mixed together and 
boiled for 10 minutes. The samples were analyzed by SDS-PAGE (100 V for 20 minutes 
followed by 300 V for ~30-35 minutes). The gel was stained with Coomassie blue, and 
de-stained with solution I (45% methanol, 9% acetic acid) for ~10 minutes and solution II 
(10% methanol and 10% acetic acid) overnight. The gel was placed in drying solution 
(30% methanol and 5% glycerol) for 1 hour, and dried between cellophane membranes.  
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2.2.6 Ni2+ Affinity Chromatography Purification for 100 mL Overexpression Cultures 
1 mL Ni2+ affinity resin suspension (Novagen) was added to an “Econo” column 
(Biorad) and rinsed with ~20 mL binding buffer (5 mM imidazole, 20 mM Tris•HCl 
(pH 8.0), 0.5 M NaCl). The sonicated supernatant was added to the top of the column and 
15 mL wash buffer (60 mM imidazole, 20 mM Tris•HCl (pH 8.0), 0.5 M NaCl) was used 
to elute all of the E. coli proteins, leaving the His•Tagged protein (Ml1682(HT), 
Ml2698(HT), or Rv3908(HT)) bound to the resin. The column was rinsed with 10 mL 
elution buffer (250 mM imidazole, 20 mM Tris•HCl (pH 8.0), 0.5 M NaCl) to elute 1 mL 
fractions containing the His•Tagged proteins. The protein concentration of each fraction 
was determined by Bradford assays and the fractions containing protein were analyzed by 
SDS PAGE.  
 
2.2.7 Ni2+ Affinity Chromatography Purification for 2 L Overexpression Cultures 
20 mL Ni2+ affinity resin suspension was added to a column (Biorad) and rinsed with 
~200 mL binding buffer, the sonicated supernatant was added to the top of the column, 
and 100 mL wash buffer was used to elute all of the E. coli proteins, leaving the 
His•Tagged proteins bound to the resin. The column was rinsed with 50 mL of elution 
buffer to elute 2 mL fractions containing the His•Tagged proteins. The protein 
concentration of each fraction was determined by Bradford assays and the fractions 
containing protein were analyzed by SDS PAGE.  
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2.2.8 Dialysis and Concentration 
Fractions containing the His•Tagged protein were combined and dialyzed using a 
Slide-A-Lyzer (10 kD MWCO) cassette (Pierce). A “step down” dialysis procedure was 
used: dialysis in buffer 1 (100 mM imidazole, 250 mM NaCl, 20 mM Tris•HCl (pH 8.0), 
10% ammonium sulfate), followed by buffer 2 (50 mM imidazole, 100 mM NaCl, 
20 mM Tris•HCl (pH 8.0), 10% ammonium sulfate), followed by buffer 3 (50 mM NaCl, 
20 mM Tris•HCl (pH 8.0), 10% ammonium sulfate) each for 1 hour and finally buffer 4 
(50 mM NaCl, 50 mM Tris•HCl (pH 7.5), 1 mM EDTA, 0.1 mM DTT, 10% ammonium 
sulfate,) for 2 hours. The dialyzed protein solutions were concentrated using Amicon 
Ultra Centrifugal filter units (Millipore) centrifuged at 4,000 RCF until the final volume 
was ~0.5-1.0 mL. 
 
2.3 Solubility Studies 
2.3.1 Overexpression of Ml1682 and Ml1682(HT) in E.coli BLR(DE3) at 10 °C 
The procedure was similar to the 100 mL overexpression of Ml1682(HT) in E.coli 
BLR(DE3) at 15 °C with the following modification: once the culture reached ~0.4 OD, 
it was placed at 10 °C with shaking for ~24 hours.  
 
2.3.2 Overexpression of Ml1682(HT) Induced with Different Concentrations of IPTG 
The procedure was similar to the 100 mL overexpression of Ml1682(HT) in E.coli 
BLR(DE3) at 15 °C with the following modification: once cultures reached ~0.6 OD, one 
culture was induced with 1 mM IPTG and the other culture was induced with 0.1 mM 
IPTG. 
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2.3.3 Overexpression of Ml1682(HT), Varying Incubation Time After Induction 
1 L LB cultures were grown at 15 °C following the same procedure for 2 L 
overexpression of Ml1682(HT) with the following modification: instead of 
overexpression after induction for ~24 hours, the cells were grown for 5 hours after 
induction. Prior to induction, 1.5 mL culture was harvested for TP=0 sample and 100 mL 
culture was harvested. Every hour after induction with 1 mM IPTG, 1.5 mL culture 
(TP=1, 2, 3, 4, and 5) and 100 mL culture was harvested. The 100 mL culture fractions 
were resuspended in Tris•HCl (pH 8.0), sonicated, and fractionated. 
 
2.3.4 Overexpression of Ml1682 and Ml1682(HT), Using the Chaperone GroESL 
pGroESL plasmid was purified from E. coli HB101 using the miniprep procedure 
detailed in section 2.1.5. A double transformation was performed by adding both 
pGroESL and pETml1682 or pET19ml1682 to E. coli BLR(DE3) competent cells. 
Ml1682 and Ml1682(HT) were overexpressed at 15 °C in the presence of the molecular 
chaperone GroESL. 	  
2.3.5 Overexpression of Ml1682 and Ml1682(HT) in E. coli Rosetta(DE3) 	  Rosetta(DE3) cells were made competent using the CaCl2 method as described in 
“Molecular Cloning, a laboratory manual.”60 50 mL prewarmed LB with 
chloramphenicol was inoculated with 5 mL Rosetta(DE3) overnight culture. The cells 
were grown at 37 °C with shaking to an OD600 of ~0.4-0.6. The cells were harvested by 
centrifugation at 4,000 RCF at 4 °C for 10 minutes. The pellet was resuspended in 25 mL 
ice-cold 50 mM CaCl2 / 10 mM Tris•HCl (pH 8.0) and centrifuged at 4,000 RCF at 4 °C 
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for 15 minutes. The pellets were resuspended in 50 mM CaCl2 / 10 mM Tris•HCl (pH 
8.0) / 15% glycerol and divided into 200 µL aliquots. Samples were stored at 4 °C for 
~18 hours. After ~18 hours, the cells were resuspended gently, quickly frozen in a dry ice 
ethanol bath, and stored at -80 °C. 
Rosetta(DE3) competent cells were transformed with pETml1682 and 
pET19ml1682. Overexpression of Ml1682 and Ml1682(HT) in Rosetta(DE3) cells was 
similar to the 100 mL overexpression of Ml1682(HT) in BLR(DE3) at 15 °C as described 
in the section 2.2.2.   
 
2.3.6 Overexpression of Ml1682 and Ml1682(HT) in Minimal Media 
Ml1682 and Ml1682(HT) were overexpressed in minimal media. pET19b in E. coli 
BLR(DE3) was used as a negative control. The procedure was similar to the 100 mL 
overexpression of Ml1682(HT) at 37 °C (section 2.2.1), but minimal media was used 
instead of LB media. Minimal media contained 200 mM sodium hydrogen phosphate, 
110 mM potassium dihydrogen phosphate, 43 mM sodium chloride, 1 M magnesium 
sulfate, 1 M calcium chloride, 20% glucose, 4.7 M ammonium chloride, and 0.1 mg/mL 
ampicillin.  
 
2.3.7 Overexpression of Ml1682(HT) in the Presence of Glycylglycine 
Three different experiments were carried out using glycylglycine: 1) 100 mL LB 
containing 500 mM glycylglycine was autoclaved. 2) 6.6 grams glycylglycine (500 mM) 
was added to 100 mL LB just prior to inoculation. 3) 6.6 grams of glycylglycine 
(500 mM) was added to 100 mL culture just prior to induction with IPTG. In all three 
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experiments, Ml1682(HT) was overexpressed in E. coli BLR(DE3) at 15 °C as described 
in section 2.2.2.    	  
2.4 Characterization of Enzymes 
2.4.1 Bradford Assay 
1-20 µL solution containing protein was added to 800 µL water and mixed well. To 
this, 200 µL Bradford dye (BioRad) was added. Protein concentration was determined by 
measuring A595 and using the standard curve shown in Fig. 34 (Appendix). 
 
2.4.2 Enzyme Assay 
Reactions with different enzyme concentrations were carried out using 50 µL of a 
standard reaction mixture containing 2 mM Ap4A, 5 mM MgCl2, 1 mM DTT, 50 mM 
Tris•HCl (pH 9) and 0.057 U/µL calf intestinal alkaline phosphatase (BioLabs) to release 
free phosphate. Reactions were incubated at 37 °C for 30 minutes and quenched with 
250 µL 2 mM EDTA. 700 µL Ames mix (6:1 0.42% ammonium molybdate in 1 N 
H2SO4 :	   10% ascorbic acid) was added before incubation at 42 °C for 20 minutes to 
produce a blue molybdophosphate complex. Phosphate was quantified by measuring A780 
where 50 nmol phosphate will yield 1 OD.  
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3. Results and Discussion 
3.1 Subcloning of pET19ml1682, pET19ml2698, and pET19rv3908  
3.1.1 Plasmid Purification 
The pETml1682, pETml2698, pETrv3908 and three samples of pET19b plasmids 
were purified from E.coli DH5α to yield DNA of sufficient quantity (see Table VII) and 
quality (see Fig. 10). DNA concentrations were determined by: 
 [𝐃𝐍𝐀]    𝐧𝐠𝛍𝐋 = 𝐀𝟐𝟔𝟎(𝐎𝐃)×𝟓𝟎(𝛍𝐠𝐦𝐋)𝐃𝐢𝐥𝐮𝐭𝐢𝐨𝐧  𝐅𝐚𝐜𝐭𝐨𝐫        Eq. 13 
 
Table VII: Quantification of pETml1682, pETml2698, pETrv3908, and pET19b. 
Plasmid [DNA] 
(ng/µL) 
Volume 
(µL) 
DNA 
(µg) 
pETml1682 170 120 20.4 
pET19b 270 120 32.4 
pETml2698 150 120 18.0 
pET19b 140 120 16.8 
pETrv3908 215 120 25.8 
pET19b 255 120 30.6 
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 A.     B.           
 
 
 
 
 
 
 
 
Figure 10: Agarose gel analysis of purified pET19b, pETml1682, and pETrv3908. 
A. pET19b and pETml1682, Lane 1: λ HindIII MWMs; Lane 2: 100 ng pET19b; Lane 3: 
100 ng pETml1682. B. pET19b and pETrv3908, Lane 1: λ HindIII MWMs; Lane 2: 100 
ng pET19b; Lane 3: 100 ng pETrv3908; Lane 4: λ HindIII MWMs. 
 
3.1.2 Restriction Enzyme Digests 
The pETml1682, pETml2698, pETrv3908 and pET19b plasmids were each digested 
with NdeI and BamHI-HF restriction enzymes. Single digests of pET19b by either NdeI 
or BamHI-HF endonucleases indicated that both enzyme digestions were complete within 
1 hour (see Fig. 11). 
A.     B.      C. 
Figure 11: Digestion of pET19b with NdeI and BamHI-HF endonucleases. A. Used for 
ml1682 subcloning. B. Used for ml2698 subcloning. C. Used for rv3908 subcloning. For 
all: Lane 1: λ HindIII MWMs; Lane 2: pET19b digested with NdeI; Lane 3: pET19b 
digested with BamHI-HF; Lane 4: λ HindIII MWMs. 
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3.1.3 Purification of Digested Plasmid and Excised Gene  
In the restriction digests, the ml1682 gene was excised from pETml1682 and ran on 
the gel as expected for DNA of 993 bp (Fig. 12A). The ml2698 gene was excised from 
pETml2698 and ran on the gel as expected for DNA of 747 bp (Fig. 12B). The rv3908 
gene was excised from pETrv3908 and ran on the gel as expected for DNA of 747 bp 
(Fig. 12C). Due to technical issues, we were unable to take a photo of the gel; however, a 
sketch is shown in Fig. 12C, and qualitatively, the gel looked similar to that in Fig. 12B 
(for ml2698). Digested ml1682, ml2698, rv3908 and pET19b were extracted from the gel 
and purified using the gene-clean kit.  
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A.         B. 
 
 
 
 
 
C. 
 
 
 
 
 
 
Figure 12: Gel purification of digested ml1682, ml2698, rv3908, and pET19b. A. ml1682: 
Lanes 1 and 6: λ HindIII MWMs; Lanes 2 and 3: digested pETml1682; Lanes 4 and 5: 
digested pET19b. B. ml2698:  Lanes 1 and 6: λ HindIII MWMs; Lanes 2 and 3: digested 
pETml2698; Lanes 4 and 5: digested pET19b. C. rv3908:  Lanes 1 and 6: λ HindIII 
MWMs; Lanes 2 and 3: digested pETrv3908; Lanes 4 and 5: digested pET19b. All were 
digested with NdeI and BamHI-HF endonucleases. For all, the digested pET19b and the 
excised gene were purified from the gel. 
 
Purity and yield of each digested gene and digested pET19b were analyzed by	  
agarose gel electrophoresis (Fig. 13A). In Fig. 13A, the concentration of digested pET19b 
is ~25 ng/µL and the concentration of ml1682 is ~5-10 ng/µL. In Fig. 13B, the 
concentration of digested pET19b is ~25 ng/µL and the concentration of ml2698 is 
~6 ng/µL. In Fig. 13C, the concentration of digested pET19b is ~25 ng/µL and in 
Fig. 13D, the concentration of rv3908 is 1.5 ng/µL.  
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 A.       B. 
 
C.       D. 
	  
 
Figure 13: Digested pET19b and excised genes (ml1682, ml2698, and rv3908) after 
purification from gels using the “gene-clean” kit. A. ml1682 and pET19b: Lanes 2 and 9: 
λ HindIII MWMs; Lanes 3 and 6: 100 ng of pET19b; Lanes 4 and 5: 1 µL and 2 µL 
digested, gel-purified ml1682, respectively; Lanes 7 and 8: 1 µL and 2 µL digested, gel-
purified pET19b, respectively. B. ml2698 and pET19b: Lanes 2 and 9: λ HindIII MWMs; 
Lanes 3 and 6: 100 ng of pET19b; Lanes 4 and 5: 1 µL and 2 µL digested, gel-purified 
ml2698, respectively; Lanes 7 and 8: 1 µL and 2 µL digested, gel-purified pET19b, 
respectively. C. rv3908 and pET19b: Lanes 2 and 9: λ HindIII MWMs; Lanes 3 and 6: 
100 ng of pET19b; Lanes 4 and 5: 1 µL and 2 µL digested, gel-purified rv3908, 
respectively; Lanes 7 and 8: 1 µL and 2 µL digested, gel-purified pET19b, respectively. 
D. rv3908: λ HindIII MWMs; Lane 3: 100 ng pET19b; Lanes 4 and 5: 1 µL and 2 µL 
digested, gel-purified rv3908, respectively. Gel “D” was done because the gene bands 
could not be visualized in gel “C”. 	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3.1.4 Ligations and Transformations 
The molecular sizes of digested pET19b, ml1682, ml2698, and rv3908 are ~5.7 kbp, 
~1 kbp, ~0.8 kbp, and ~0.8 kbp, respectively. For 75 ng pET19b, 13.5 ng ml1682 is 
required for a 1:1 ratio (Table IV), for 75 ng pET19b, 10.2 ng ml2698 is required for a 
1:1 ratio (Table V), and for 75 ng pET19b, 6.75 ng rv3908 gene is required to make a 
1:0.69 ratio (Table VI). It was impossible to obtain a 1:1 ratio for rv3908 due to its low 
concentration, and lowering the amount of pET19b would have lowered the likelihood of 
ligation.  
Ligation mixture A containing digested, gene-cleaned pET19b (but no digested, 
gene-cleaned gene) was used as a negative ligation control; pUC19 was used as a positive 
transformation control. As seen in Table IV, there were 3-4 times more colonies that 
resulted from ligations of plasmid and gene than from plasmid alone. However, as seen in 
Tables V and VI, transformation with ligation mixture A yielded as many colonies as the 
ligations B-D containing both pET19b and gene, indicating that the double digestions 
with NdeI and BamHI-HF were not 100% complete, with some of the plasmids digested 
by only one restriction enzyme, allowing these complementary sticky ends to reanneal. 
However, in each case, at least one colony for each subclone (pET19ml1682, 
pET19ml2698, and pET19rv3908) was determined to contain the proper subcloned 
plasmid. 
Twelve colonies were analyzed for possible pET19ml1682 subclones, twenty-four 
colonies were analyzed for possible pET19ml2698 subclones, and twenty-four colonies 
were analyzed for possible pET19rv3908 subclones.  
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pET19b is ~5.7 kbp and while pET19ml1682, pET19ml2698, and pET19rv3908 are 
6.6 kbp, 6.4 kbp, and 6.4 kbp, respectively, and thus the subclones containing the genes 
would run slower on an agarose gel. Of the twelve colonies, ten appear to contain 
pET19ml1682 in Fig. 14A. Of the twenty-four colonies, two appear to contain 
pET19ml2698 in Fig. 14B. Of the twenty-four colonies, one appears to contain 
pET19rv3908.  
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A. 
 
B. 
 
 
 
 
 
C. 
 
Figure 14: Miniprepped DNA: subcloned pET19ml1682, pET19ml2698, and 
pET19rv3908. A. pET19ml1682: Lanes 1 and 14: 100 ng pET19b; Lanes 2-13: 
miniprepped DNA. Lanes 2-3, 5-8, and 10-13 contain successfully subcloned 
pET19ml1682. B. pET19ml2698: Lanes 1, 14, 15, and 28: 100 ng pET19b; Lanes 2-13, 
and 16-27: miniprepped DNA. Lanes 16 and 18 contain successfully subcloned 
pET19ml2698 (boxed in red). C. pET19rv3908:  Lane 1, 12, 13 and 24: 100 ng pET19b; 
Lanes 2-11, 14-23: miniprepped DNA; Lane 18: contains successfully subcloned 
pET19rv3908 (boxed in red). In B and C: most of the other lanes contained pET19b that 
had religated; this would be due to less than 100% cleavage by NdeI and/or BamHI-HF 
endonucleases.  
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3.1.5 Verification of Subcloning 
To verify that pET19ml1682 was subcloned, the purified plasmids were digested 
with EcoRV endonuclease. EcoRV cleaves pET19b to produce 4229 bp and 1488 bp 
fragments, whereas EcoRV cleaves pET19ml1682 to produce 4229 bp and 2319 bp 
fragments. All ten purified plasmids that were tested yielded bands of the proper size for 
pET19ml1682 (Fig. 15A), indicating success in subcloning pET19ml1682.  
The two possible subclones of pET19ml2698 (colonies B4 and B6) were digested 
with NdeI and BamHI-HF and separately with EcoRV. EcoRV cleaves pET19ml2698 to 
produce 4229 bp and 2229 bp fragments (Fig. 15B), thus indicating that ml2698 has been 
subcloned into pET19b to yield the sublone pET19ml2698. NdeI and BamHI-HF cleave 
ml2698 from pET19ml2698 to produce 5706 bp and 752 bp fragments corresponding to 
pET19b and ml2698, respectively (Fig. 15B). 
Likewise, the possible subclone of pET19rv3908 (colony C4) yielded similar results 
to those discussed above for pET19ml2698 as the genes of rv3908 and ml2698 are the 
same size. These digests indicate that rv3908 has been subcloned into pET19b to yield 
the subclone pET19rv3908.  
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A.  
 
B.  
 
C. 
 
Figure 15: Verification of the subcloning of pET19ml1682, pET19ml2698, and 
pET19rv3908. A. pET19ml1682: Lanes 1 and 14: λ HindIII MWMs; Lanes 2 and 13: 
150 ng pET19b digested with EroRV; Lanes 3-12: miniprepped pET19ml1682 digested 
with EcoRV. B. pET19ml2698: Lanes 1 and 8: λ HindIII MWMs; Lane 2: 150 ng 
pET19b digested with EcoRV; Lanes 3 and 4: miniprepped pET19ml2698 digested with 
EcoRV; Lane 5: pET19b digested with NdeI and BamHI-HF; Lanes 6 and 7: 
miniprepped pET19ml2698 digested with NdeI and BamHI-HF; C. pET19rv3908: Lanes 
1 and 6: λ HindIII MWMs; Lane 2: 150 ng pET19b digested with EcoRV; Lane 3: 
miniprepped pET19rv3908 digested with EcoRV; Lane 4: pET19b digested with NdeI 
and BamHI-HF; Lane 5: miniprepped pET19rv3908 digested with NdeI and BamHI-HF. 
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3.2 Ml1682(HT), Ml2698(HT) and Rv3908(HT) Overexpression and Protein 
Purification 
3.2.1 Overexpression of Ml1682(HT) in E.coli BLR(DE3) in 100 mL LB at 37 °C 
Ml1682(HT) protein expressed well in E.coli BLR(DE3) at 37 °C but it was very 
insoluble. Most of the Ml1682(HT) was in the sonicated pellet and very little was in the 
sonicated supernatant (as seen in Fig. 16 and as observed with ApnAase enzyme assays of 
the sonicated supernatant as compared to the sonicated supernatant of E. coli BLR(DE3) 
containing pET19b). 
 
 
Figure 16: Overexpression of Ml1682(HT) in E.coli BLR(DE3) at 37 °C in 100 mL LB 
media. Lane 1: MWMs; Lane 2: prior to induction; Lane 3: 1 hour after induction; 
Lane 4: 2 hours after induction; Lane 5: 3 hours after induction; Lane 6: whole cell crude 
extract; Lane 7: sonicated supernatant; Lane 8: sonicated pellet. An arrow points to 
Ml1682(HT). 	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3.2.2 Solubility Studies 
Due to the insolubility of Ml1682(HT), a variety of methods were used to try to 
increase the solubility of Ml1682(HT), as seen in Table VIII. All methods were tested 
using Bradford assays, SDS PAGE, and ApnAase enzyme assays.   
 
Table VIII: Methods to increase protein solubility:  A check mark indicates that the 
method did increase protein solubility compared to the other methods but not by a 
significant amount.  
Methods Ml1682(HT) 
Vary 
Temperature 
37 °C 
15 °C 
✔ 
10 °C 
Vary 
[IPTG] 
1 mM 
✔ 
0.1 mM 0.01 mM 
Incubation Time 
After Induction 
 1 hr 2 hrs 3 hrs 4 hrs 5 hrs 
Incorporate GroESL Overexpressed at 15 °C 
Rosetta(DE3) Overexpressed at 15 °C 
Minimal Media Overexpressed at 15 °C 
Glycylglycine 
Added  
Prior to  
Autoclaving 
Added  
 Prior to 
Inoculation 
Added  
 Prior to 
Induction 
 
Lowering the temperature at which overexpression was achieved from 37 °C to 
15 °C did improve the solubility of Ml1682(HT) (compare Fig. 16 to Fig. 17A). While it 
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may be difficult to see the difference by SDS PAGE, the sonicated supernatant from the 
15 °C overexpression had ~25% more ApnAase activity than the sonicated supernatant 
from the 37 °C overexpression. Therefore we decided to test overexpression at 10 °C, but 
saw very little difference in solubility of Ml1682(HT) between overexpression at 10 °C 
vs. 15 °C (compare Fig. 17A and 17B). Since there was more expressed protein at 15 °C, 
than at 10 °C, all other experiments were carried out using 15 °C as the temperature for 
overexpression.  
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A.	  
	  	  
B. 
 
Figure 17: Overexpression of Ml1682(HT) in E.coli BLR(DE3) in 100 mL LB media at 
varying temperatures. A. 15 °C: Lane 1: MWMs; Lane 2: prior to induction; Lane 3: 
20 hours after induction; Lane 4: whole cell crude extract; Lane 5: freeze thaw extract; 
Lane 6: sonicated supernatant; Lane 7: sonicated pellet. B. 10 °C: Lane 1: MWMs; 
Lane 2: prior to induction; Lane 3: 22 hour after induction; Lane 4: sonicated supernatant; 
Lane 5: sonicated pellet; Lane 6: whole cell crude extract; Lane 7: freeze thaw extract. 
An arrow points to Ml1682(HT). 
 
Lowering the concentration of IPTG did not increase the solubility of Ml1682(HT) 
(Fig. 18). Therefore all other experiments were carried out using 1 mM IPTG for 
induction of overexpression.  
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Figure 18: Overexpression of Ml1682(HT) in E.coli BLR(DE3) at with varying IPTG 
concentrations. Lane 1: MWMs; Lane 2-4: induction with 0.1 mM IPTG. Lane 2: whole 
cell crude extract; Lane 3: sonicated supernatant; Lane 4: sonicated pellet; Lane 5-7: 
induction with 0.01 mM IPTG. Lane 5: whole cell crude extract; Lane 6: sonicated 
supernatant; Lane 7: sonicated pellet. An arrow points to Ml1682(HT). 
 
Shortening the time for overexpression after induction with IPTG from ~22-24 hours 
to five hours or less did not increase Ml1682(HT) solubility but did decrease expression. 
Only samples from 3-5 hours after induction are shown in Fig. 19, however samples for 1 
and 2 hours after induction did not contain any more soluble Ml1682(HT).  
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Figure 19: Overexpression of Ml1682(HT) in E.coli BLR(DE3) at 15 °C varying 
expression time after induction. Lane 1: MWMs; Lanes 2-4: 3 hours after induction with 
IPTG. Lane 2: whole cell crude extract; Lane 3: sonicated supernatant; Lane 4: sonicated 
pellet; Lanes 5-7: 4 hours after induction with IPTG. Lane 5: whole cell crude extract; 
Lane 6: sonicated supernatant; Lane 7: sonicated pellet; Lane 8-10: 5 hours after 
induction with IPTG. Lane 8: whole cell crude extract; Lane 9: sonicated supernatant; 
Lane 10: sonicated pellet. An arrow points to Ml1682(HT). 	  
Ml1682(HT) overexpressed in the presence of overexpressed chaperone did not 
increase the solubility of Ml1682(HT) (Fig. 20A). Overexpression of Ml1682(HT) in the 
E. coli Rosetta(DE3) strain (containing tRNAs for rare codons) also did not increase the 
solubility of Ml1682(HT) (Fig. 20 B). 
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A. 
 	    
B.  
	  
Figure 20: Use of the chaperone GroESL and E. coli Rosetta(DE3) (codes for tRNAs for 
rare codons).	   A. Overexpression of Ml1682(HT) in E.coli BLR(DE3) with GroESL. 
Lane 1: MWMs; Lane 2: prior to induction; Lane 3: 24 hours after induction; Lane 4: 
whole cell crude extract; Lane 5: sonicated supernatant; Lane 6: sonicated pellet. 
B. Overexpression of Ml1682(HT) in E. coli Rosetta(DE3). Lane 1: MWMs; Lane 2: 
prior to induction; Lane 3: 23 hours after induction; Lane 4: whole cell crude extract; 
Lane 5: sonicated supernatant; Lane 6: sonicated pellet. An arrow points to Ml1682(HT).	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Another method that can slow down cell culture growth and thus allow proteins to 
fold properly so they are soluble is to grow the cells in minimal media. However, 
overexpression in minimal media did not increase the solubility of Ml1682(HT) (Fig. 21).  
 
 
Figure 21:	  Overexpression of Ml1682 and Ml1682(HT) in E.coli BLR(DE3) in minimal 
media. Lane 1: MWMs; Lane 2-4: pET19b. Lane 2: whole cell crude extract; Lane 3: 
sonicated supernatant; Lane 4: sonicated pellet; Lane 5-7: Ml1682(HT). Lane 5: whole 
cell crude extract; Lane 6: sonicated supernatant; Lane 7: sonicated pellet; Lane 8-10: 
Ml1682. Lane 8: whole cell crude extract; Lane 9: sonicated supernatant; Lane 10: 
sonicated pellet. An arrow points to Ml1682 and Ml1682(HT). 	  
Studies have shown that adding glycylglycine to rich media could increase protein 
solubility for some proteins. In all three experiments using glycylglycine, Ml1682(HT) 
was equally insoluble, thus for this protein, glycylglycine does not help Ml1682(HT) to 
be more soluble (see Fig. 22) 
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A. 
 
B. 
 
C.  
 
Figure 22:	  Effect of glycylglycine on protein solubility. Overexpression of Ml1682(HT) 
in E.coli BLR(DE3). A. Glycylglycine was added to LB media prior to autoclaving. 
B. Glycylglycine was added to LB media just prior to inoculation. C. Glycylglycine was 
added to LB media just prior to induction. For all, Lane 1: MWMs; Lane 2: prior to 
induction; Lane 3: ~24 hours after induction; Lane 4: whole cell crude extract; Lane 5: 
sonicated supernatant; Lane 6: sonicated pellet; Lane 7: prior to induction. An arrow 
points to Ml1682(HT). 
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None of the methods that we explored increased the solubility of Ml1682 or 
Ml1682(HT). Upon further reading of the literature, it appears that expression of soluble 
M. leprae proteins can be challenging.  
Another method that we did not try was to add a solubility tag to the protein. 1) This 
would have required further subcloning, which we did not have time to do and 2) We 
have not had success with solubility tags including the use of the maltose binding protein, 
which yielded a soluble but misfolded ApnAase from Legionella pneumophila. We will 
certainly further investigate other methods to attempt to express soluble Ml1682 and 
Ml1682(HT). It is preferential to express soluble protein vs. solubilizing insoluble protein 
because it is not known if activity is lost in the process of solubilization.  
 
3.2.3 2 L Overexpression of Ml1682(HT) in E.coli BLR(DE3) at 15 °C 
The overexpression of Ml1682(HT) in E. coli BLR(DE3) was scaled up to 2 L (two 
1 L cultures) to generate enough protein to purify. The expression and solubility of 
Ml1682(HT) was comparable to the 100 mL culture, as seen in Fig. 23.  	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Figure 23: Overexpression of Ml1682(HT) in E.coli BLR(DE3) cells at 15 °C in 1 L LB 
media. Lane 1: MWMs; Lane 2: prior to induction; Lane 3: 22 hour after induction; 
Lane 4: whole cell crude extract; Lane 5: sonicated supernatant; Lane 6: sonicated pellet. 
An arrow points to Ml1682(HT). 
 
3.2.4 Purification of Ml1682(HT) in E.coli BLR(DE3)  
After sonication of the harvested cells, the sonicated supernatant was fractionated by 
Ni2+ affinity chromatography. All other proteins eluted from the column with the addition 
of wash buffer, while the 35 kDa Ml1682(HT) protein did not elute until elution buffer 
was added over the column (see Fig. 24). The Ni2+ affinity chromatography did isolate 
purified Ml1682(HT); however, the protein concentration was too low to dialyze and 
concentrate. By using Bradford assays, we determined that Ml1682(HT) was lost in the 
dialysis process, probably through precipitation. Thus increasing Ml1682(HT) solubility 
will be essential in order to purify the protein for characterization. 	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Figure 24: Purification of Ml1682(HT) by Ni2+ affinity chromatography. Lane 1: 
sonicated supernatant; Lanes 2 and 3: wash fractions 3 and 4; Lanes 4-9: elute fractions 
4-7, 9, and 11 (Ml1682(HT) boxed in red); Lane 10: MWMs. 	  
3.2.5 Overexpression and Purification of Ml2698(HT)  
The overexpression and solubility of Ml2698(HT) was comparable with that of 
Ml1682(HT) (compare Fig. 23 and 25). The 30 kDa Ml2698(HT) protein was also 
purified readily from the other proteins in the sonicated supernatant via the Ni2+ affinity 
chromatography (see Fig. 26). 
However, there was even less soluble Ml2698(HT) protein that eluted from the Ni2+ 
column (see Fig. 26), and not enough to dialyze and concentrate.  
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Figure 25: Overexpression of Ml2698(HT) in E.coli BLR(DE3) at 15 °C in 1 L LB 
media. Lane 1: MWMs; Lane 2: Prior to induction; Lane 3: 22 hours after induction; 
Lane 4: whole cell crude extract; Lane 5: sonicated supernatant; Lane 6: sonicated pellet. 
An arrow points to Ml2698(HT). 	  
 
Figure 26: Purification of Ml2698(HT) by Ni2+ affinity chromatography. Lane 1: 
sonicated supernatant; Lanes 2-3: wash fractions 2-3; Lanes 4-9: elute fractions 3-7, and 
10 (Ml2698(HT) boxed in red); Lane 10: MWMs.	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3.2.6 Overexpression and Purification of Rv3908(HT)  
 Rv3908(HT) protein expressed well in E.coli BLR(DE3) at 15 °C and it was more 
soluble than Ml1682(HT) or Ml2698(HT) as seen in Fig. 27. The 30 kDa Rv3908(HT) 
protein also purified well from the other proteins over the Ni2+ affinity chromatography 
column with significantly more pure Rv3908(HT) eluting from the column (Fig. 28). 
However Rv3908(HT) precipitated during dialysis and thus we will need to 
determine dialysis conditions for this protein. 
 
  
Figure 27: Overexpression of Rv3908(HT) in E.coli BLR(DE3) at 15 °C in 1 L LB 
media. Lane 1: MWMs; Lane 2: Prior to induction; Lane 3: 22 hours after induction; 
Lane 4: whole cell crude extract; Lane 5: sonicated supernatant; Lane 6: sonicated pellet. 
An arrow points to Rv3908(HT). 	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Figure 28: Purification of Rv3908(HT) by Ni2+ affinity chromatography. Lane 1: 
sonicated supernatant; Lanes 2-4: wash fractions 2-4; Lane 5-9: elute fractions 4, 6-7, and 
11-12 (Rv3908(HT) boxed in red); Lane 10: MWMs. 	  	  
	   68	  
4. Conclusions 
The genes ml1682, ml2698, and rv3908 have been subcloned into pET19b for 
overexpression of His•Tagged proteins. Ml1682(HT), Ml2698(HT), and Rv3908(HT) 
have been expressed and show ApnAase activity in the whole cell crude extract above 
that of the negative control. Rv3908(HT) was relatively more soluble then either 
Ml1682(HT) or Ml2698(HT), which were both very insoluble. Rv3908(HT) was purified 
over a Ni2+ affinity column, but precipitated during dialysis following chromatography. 
Future work will include determining dialysis conditions that will not precipitate 
Rv3908(HT) followed by enzyme characterization. A variety of methods were used to try 
to increase the solubility of Ml1682(HT), however Ml1682(HT) is still very insoluble. 
Purification of Ml1682(HT) and Ml2698(HT) via Ni2+ affinity chromatography was 
successful but yielded insufficient quantities of purified protein to be able to dialyze and 
analyze; these proteins’ solubility will need to be increased for further purification and 
characterization of these enzymes. 
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Figure 29: Leprosy classification: Lepromatous leprosy, Intermediate state, and 
Tuberculoid leprosy. Intermediate state can be either borderline tuberculoid or borderline 
lepromatous. Tuberculoid leprosy is usually stable and rarely contagious with symptoms 
of hypopigmentation with loss of sensation. Whereas lepromatous leprosy is dynamic, 
contagious, involves more severe disability and nerve damage. Tuberculoid leprosy can 
easily turn into lepromatous leprosy if the immune system is not strong enough.  	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Figure 30: Current antibiotics used to treat MTB, and their targets. 	  	  	  	  
	   A3	  
	  
	  
Figure 31: The transmission cycle of MTB. A. Transmission stage: MTB has a nearly 
impenetrable lipid-rich cell wall that enables it to survive in air droplets. Once inhaled, 
MTB invades the pulmonary alveoli and is taken up by macrophages. MTB takes over 
the cells’ internal machinery to prevent further internal phagocytic destruction and starts 
to replicate. B. Immune response stage: The infected macrophages signal other immune 
cells to attack MTB. C. Latency stage: In most people, the immune system is able to 
confine the infection to granulomas, where it can be contained for years. D. Activation 
stage: When the immune system cannot control the infection, the granulomas break 
down, releasing MTB throughout the body.  	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Figure 32: Throughout history, TB has killed more people than any other infectious 
disease. Over a billion people have died from TB in last 200 years. 	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Figure 33: Ni2+ affinity chromatography used to purify Histidine-tagged proteins.   	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Figure 34: Standard curve for Bradford protein analysis. Using BSA standard. 
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